Antigen News and Research

RSS

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

Natural killer cells are major weapons in the body's immune system. They keep the body healthy by knocking off tumors and cells infected with viruses, bombarding them with tiny lethal pellets. But natural killer cells are powerless against HIV, a fact that has bedeviled science for over 20 years.

20 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Inovio Pharmaceuticals, Inc. , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX-B, a DNA vaccine for the prevention of HIV infection.

18 Nov 2010

National pilot program facilitates kidney paired-donation transplants

A computer algorithm developed at Carnegie Mellon University matched living kidney donors with medically compatible transplant candidates late last month as the national Organ Procurement and Transplantation Network (OPTN), operated by the United Network for Organ Sharing (UNOS), began a national pilot program to increase the number of kidney paired-donation (KPD) transplants.

17 Nov 2010

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

The National Institutes of Health (NIH) has awarded $10 million to the Georgia Institute of Technology, Emory University and PATH, a Seattle-based nonprofit organization, to advance a technology for the painless, self-administration of flu vaccine using patches containing tiny microneedles that dissolve into the skin.

17 Nov 2010

Never-smokers have better chance of surviving head and neck cancer

Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.

17 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

Domainex, Sigma-Aldrich enter collaboration to study epigenetic proteins

Domainex Ltd., the Contract Research Organization committed to excellence in drug discovery, today announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics. These epigenetic proteins regulate DNA expression and can be critical to cancer and stem cell biology research. Funding from the UK Government-backed Technology Strategy Board will support this work.

15 Nov 2010

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Diamyd completes patient screening for DiaPrevent Phase III study

Diamyd Medical has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.

10 Nov 2010

Albert Einstein researcher receives Medal of Honor from American Cancer Society

Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

10 Nov 2010

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Antigen News and Research

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Research suggests new therapeutic approach to prevent transplant rejection

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

National pilot program facilitates kidney paired-donation transplants

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

Never-smokers have better chance of surviving head and neck cancer

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Domainex, Sigma-Aldrich enter collaboration to study epigenetic proteins

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Immunologix partners with Genscript to develop human antibody therapeutics

Diamyd completes patient screening for DiaPrevent Phase III study

Albert Einstein researcher receives Medal of Honor from American Cancer Society

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Potential new biomarkers for very early prostate cancer

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Gene fusion prostate cancers susceptible to secondary mutations

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News